The Experience of Hepatitis C Screening among Prison Inmates with Drug Injection History

Document Type : Original Article(s)

Authors

1 Department of Health, Prisons Organization, Isfahan, Iran.

2 Researcher, Infectiuos and Tropical Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

3 Specialist in Community Medicine, Disease Control Unit, Isfahan Province Health Center, Isfahan University of Medical Sciences, Isfahan, Iran.

4 Technical Manager, Infectious and Tropical Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

5 Infectious and Tropical Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

6 Associate Professor, Department of Infectious Diseases, School of Medicine and Infectious and Tropical Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

7 Associate Professor, Department of Gastroenterology, School of Medicine and Infectious and Tropical Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Abstract

Background: Hepatitis C is a major worldwide problem with remarkable medical burden which is emerging mostly due to intravenuos drug abuse. The prevalence of hepatitis C infection is higher among prison inmates because of the high proportion of injecting drug users. So, the aim of this study was to determine the seroprevalnce of hepatitis C infection among prisoners with history of intravenous drug abuse in Isfahan province-Iran.Methods: In this cross-sectional study, active and inactvie intravenous drug abusers were enrolled into study volluntarily with ethical considerations. Participants were interviwed using a structured questionnaire and a blood sample was collected for detection HCV antibody using ELISA method.Finding: From 6000 prison inmates in Isfahn central prison and Assadabad Camp, approximatly 20 percent (1200 ones) had hsitory of intravenous drug abuse from which, 951 ones (80%) were intered in this study. The prevalenc of HCV infection was 42 percent and the main factores earned from this project experience were: problem in giving samples, problem in prison interance, separate interveiw and sample collecting, and desirable participants’ cooperation.Conclusion: According to success in obtaning nearly 80% of prison inmates with history of drug abuse, this is a good experience for other investigators and health directors to design simillar studies or executive protocols.

Keywords

References

  1. National Institutes of Health Consensus Devel- opment Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002. Hepatology 2002; 36(5 Suppl 1): S3-20.
  2. Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3(2): 41-6.
  3. El Saadany S, Coyle D, Giulivi A, Afzal M. Economic burden of hepatitis C in Canada and the potential impact of prevention. Results from a disease model. Eur J Health Econ 2005; 6(2): 159-65.
  4. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an Emerging Infection. Archives of Iranian Medicine 2005; 8(2): 84-90.
  5. Kafi-abad SA, Rezvan H, Abolghasemi H, Tale- bian A. Prevalence and trends of human immuno-deficiency virus, hepatitis B virus, and hepatitis C virus among blood donors in Iran, 2004 through 2007. Transfusion 2009; 49(10): 2214-20.
  6. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epi- demiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008; 372(9651): 1733-45.
  7. Zamani S, Kihara M, Gouya MM, Vazirian M, Nassirimanesh B, Ono-Kihara M, et al. High prevalence of HIV infection associated with in- carceration among community-based injecting drug users in Tehran, Iran. J Acquir Immune Defic Syndr 2006; 42(3): 342-6.
  8. Mirahmadizadeh AR, Kadivar MR, Ghane Shi- razi R, Fararooei M. Prevalence of HIV infection among intravenous drug addicts in Shiraz. Journal of Gorgen Univrsity Medicine Sci 2001; 3(39): 41.
  9. Mir-Nasseri MM, Poustchi H, Nasseri- Moghadam S, Nouraie SM, Tahaghoghi S, Af- shar P. HCV in intravenous drug users. Govaresh 2005; 2: 80-6.
  10. Zali MR, Aghazadeh R, Nowroozi A, Amir- Rasouly H. Anti-HCV antibody among Iranian IV drug users: is it a serious problem? Archives of Iranian Medicine 2001; 4(3): 115-9.
  11. Zamani S, Ichikawa S, Nassirimanesh B, Vazi- rian M, Ichikawa K, Gouya MM, et al. Preva- lence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy 2007; 18(5): 359-63.
  12. Mathei C, Robaeys G, van Damme P, Buntinx F, Verrando R. Prevalence of hepatitis C in drug us- ers in Flanders: determinants and geographic dif- ferences. Epidemiol Infect 2005; 133(1): 127-36.
  13. Mirahmadizadeh AR, Kadivar MR, Hemmati AR, Javadi A. Infection with HIV and hepatitis C and B viruses among injecting drug users in Shi- raz, Southern Iran. International Conference on AIDS 2004; 15(11): 16.
  14. Javadi AA, Avijgan M, Hafizi M. Prevalence of HBV and HCV Infections and Associated Risk Factors in Addict Prisoners. Iranian J Publ Health Iranian J Publ Health 2006; 35(4): 33-6.
  15. Alizadeh AH, Alavian SM, Jafari K, Yazdi N. Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan--Iran. World J Gastroenterol 2005; 11(26): 4085-9.
  16. Rowhani Rahbar A, Rooholamini S, Khoshnood K. Prevalence of HIV infection and other blood- borne infections in incarcerated and non- incarcerated injection drug users (IDUs) in Mashhad, Iran. International Journal of Drug Policy 2004; 15(2): 151-5.
  17. Pourahmad M, Javadi AA, Karimi I, Ataei B, Kassaian N. Seroprevalence of and risk factors associated with hepatitis B, hepatitis C and hu- man immunodeficiency virus among prisoners in Iran. Infect Dis Clin Prac 2007; 15(6): 368-72.
  18. Zakizad M, Salmeh F, Yaghoobi T, Yaghoubian M, Nesami MB, Esmaeeli Z, et al. Seropreva- lence of hepatitis C infection and associated risk factors among addicted prisoners in Sari-Iran. Pak J Biol Sci 2009; 12(14): 1012-8.
Journal of Isfahan Medical School
Volume 28, Issue 0
November and December 2011
Pages 1565-1571

Files

History

  • Receive Date: 21 March 2011
  • Revise Date: 27 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics